Sangamo Therapeutics (NASDAQ:SGMO) was upgraded by equities researchers at TheStreet from a “d+” rating to a “c-” rating in a report issued on Tuesday, TheStreetRatingsTable reports.
Several other equities research analysts also recently commented on SGMO. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of Sangamo Therapeutics in a report on Wednesday, December 16th. Bank of America began coverage on Sangamo Therapeutics in a report on Tuesday, September 8th. They issued a “buy” rating and a $20.00 price objective for the company. BidaskClub raised Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday. ValuEngine raised Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, December 1st. Finally, Zacks Investment Research downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 11th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Sangamo Therapeutics presently has a consensus rating of “Buy” and an average price target of $17.00.
Shares of SGMO opened at $18.18 on Tuesday. The stock has a market capitalization of $2.57 billion, a P/E ratio of -21.90 and a beta of 2.13. Sangamo Therapeutics has a twelve month low of $4.81 and a twelve month high of $18.64. The company has a 50 day moving average of $11.45 and a 200-day moving average of $10.80.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Wednesday, November 4th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.23. The company had revenue of $57.76 million during the quarter, compared to analysts’ expectations of $25.11 million. Sangamo Therapeutics had a negative net margin of 91.17% and a negative return on equity of 23.12%. The business’s quarterly revenue was up 163.1% on a year-over-year basis. During the same period last year, the business earned ($0.24) EPS. Equities research analysts forecast that Sangamo Therapeutics will post -1.12 EPS for the current year.
In other Sangamo Therapeutics news, Director Saira Ramasastry sold 10,000 shares of the firm’s stock in a transaction on Thursday, December 17th. The stock was sold at an average price of $13.27, for a total transaction of $132,700.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.80% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the company. State of Wisconsin Investment Board lifted its holdings in shares of Sangamo Therapeutics by 0.5% during the second quarter. State of Wisconsin Investment Board now owns 178,200 shares of the biopharmaceutical company’s stock worth $1,597,000 after buying an additional 900 shares in the last quarter. California State Teachers Retirement System lifted its holdings in shares of Sangamo Therapeutics by 0.7% during the second quarter. California State Teachers Retirement System now owns 174,976 shares of the biopharmaceutical company’s stock worth $1,568,000 after buying an additional 1,190 shares in the last quarter. Virginia Retirement Systems ET AL lifted its holdings in shares of Sangamo Therapeutics by 4.4% during the third quarter. Virginia Retirement Systems ET AL now owns 28,300 shares of the biopharmaceutical company’s stock worth $267,000 after buying an additional 1,200 shares in the last quarter. AXA S.A. lifted its holdings in shares of Sangamo Therapeutics by 11.0% during the third quarter. AXA S.A. now owns 13,100 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 1,300 shares in the last quarter. Finally, American International Group Inc. lifted its holdings in shares of Sangamo Therapeutics by 3.6% during the second quarter. American International Group Inc. now owns 70,421 shares of the biopharmaceutical company’s stock worth $631,000 after buying an additional 2,417 shares in the last quarter. 54.46% of the stock is owned by institutional investors.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, a biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression.
Featured Story: Earnings Reports